Emcure Pharma IPO: Allotment, GMP, Listing Date & More Details

ostpmedia

6 months ago

Emcure Pharma to Open Its IPO for Bidding on July 03 — *Photo: Emcure*

Emcure Pharma IPO: Allotment, GMP, Listing Date & More Details

Emcure Pharma, a prestigious Pune-based pharmaceutical business, recently completed its much-anticipated initial public offering (IPO). This page discusses the subscription information, grey market premium (GMP), allocation status, and listing date for Emcure Pharma’s IPO.

IPO Details

Opening and Closing Dates

The Emcure Pharma IPO began on July 3 and ended on July 5, 2023, with strong investor involvement and interest.

Price Band

Emcure Pharma’s IPO pricing ranged from ₹960 to ₹1,008 per share, aligning with its market positioning and valuation expectations.

Subscription Details

Overall Subscription

Emcure Pharma’s IPO was oversubscribed by an astonishing 67.87 times, with investors bidding for 93 crore equity shares instead of the 1.37 crore shares issued.

Category-wise Subscription

Qualified Institutional Buyers (QIBs): Subscribed at an astonishing rate of 195.83 times.
Non-Institutional Investors: Subscribed 48.32 times.
Retail Investors: Subscribed 7.21 times.
Employees: Subscribed 8.81 times.

Grey Market Premium (GMP)

Current GMP

According to reports, Emcure Pharma shares are currently trading at a grey market premium (GMP) of ₹360 per share. GMP represents the premium at which IPO shares are traded prior to their official listing on stock exchanges.

How to Check Allotment Status

Investors can check the allotment status of Emcure Pharma IPO through various channels:

Registrar’s Website

Choose ‘Emcure Pharma’ from the list of companies.
Enter your PAN, application number, DP/Client ID, or account number/IFSC.
Submit to check the application status and allotted shares.

BSE and NSE Websites

BSE: Navigate to the equity section, select ‘Emcure Pharma’, and enter application number and PAN.
NSE: Log in to check IPO allotment status directly.

Listing Date

Emcure Pharma’s shares will be launched on the public exchanges on July 10, marking an important milestone for both the firm and its investors.

Conclusion

Emcure Pharma’s IPO has generated significant investor interest, as evidenced by its high subscription numbers and strong grey market performance. Investors should stay informed through official sources for credible information.